Home
EYPT
EYPT News

Latest EyePoint Pharmaceuticals Inc. (EYPT) News on September 16, 2025

MT Newswires

3 months ago

RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire

4 months ago

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire

4 months ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

MT Newswires

4 months ago

Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire

4 months ago

EyePoint Announces Participation at Upcoming Investor Conferences

New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Simply Wall St.

4 months ago

New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Simply Wall St.

4 months ago

Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks

4 months ago

EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

4 months ago

EyePoint Pharmaceuticals: Q1 Earnings Snapshot

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

4 months ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

GlobeNewswire

5 months ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation

Simply Wall St.

5 months ago

Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

GlobeNewswire

6 months ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k

Simply Wall St.

6 months ago

Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k

Thomson Reuters StreetEvents

6 months ago

Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call

EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ...

GuruFocus.com

6 months ago

EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ...

EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

6 months ago

EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates

Zacks

6 months ago

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates

Associated Press Finance

6 months ago

EyePoint Pharmaceuticals: Q4 Earnings Snapshot

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

6 months ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result

GuruFocus.com

6 months ago

Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire

6 months ago

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

GlobeNewswire

7 months ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

GlobeNewswire

7 months ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks

7 months ago

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

MT Newswires

7 months ago

EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell

MT Newswires

7 months ago

Top Premarket Decliners

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

GlobeNewswire

7 months ago

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

GlobeNewswire

8 months ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss

Simply Wall St.

8 months ago

Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

GlobeNewswire

8 months ago

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

GlobeNewswire

8 months ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

MT Newswires

8 months ago

Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target

EyePoint reports inducement grants under NASDAQ listing rule

TipRanks

9 months ago

EyePoint reports inducement grants under NASDAQ listing rule

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

9 months ago

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint doses first patient in second Phase 3 LUCIA clinical trial

TipRanks

9 months ago

EyePoint doses first patient in second Phase 3 LUCIA clinical trial

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire

9 months ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?

Zacks

10 months ago

Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?

EyePoint price target lowered to $33 from $38 at Baird

TipRanks

10 months ago

EyePoint price target lowered to $33 from $38 at Baird

EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates

Zacks

10 months ago

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

10 months ago

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

10 months ago

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing

Simply Wall St.

10 months ago

With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire

10 months ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

MT Newswires

a year ago

EyePoint Pharmaceuticals Prices $140 Million Public Offering

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?

Zacks

a year ago

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

Benzinga

a year ago

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

ANI Pharmaceuticals price target raised to $62 from $60 at Truist

TipRanks

a year ago

ANI Pharmaceuticals price target raised to $62 from $60 at Truist

MT Newswires

a year ago

Scotiabank Initiates EyePoint Pharmaceuticals at Sector Outperform With $18 Price Target

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

MT Newswires

a year ago

Jefferies Initiates EyePoint Pharmaceuticals at Buy

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 08/22/2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Some Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Estimates

Simply Wall St.

a year ago

Some Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Estimates

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates

Simply Wall St.

a year ago

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?

Simply Wall St.

a year ago

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire

a year ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

Zacks

a year ago

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

a year ago

EyePoint Pharmaceuticals: Q2 Earnings Snapshot

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Refreshes Board of Directors

GlobeNewswire

a year ago

Milestone Pharmaceuticals Refreshes Board of Directors

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

GlobeNewswire

a year ago

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

GlobeNewswire

a year ago

EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?

Zacks

a year ago

Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

GlobeNewswire

a year ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller

AFP

a year ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up

AFP

a year ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally

AFP

a year ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

a year ago

Best Date Night Fragrance in 2024

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

a year ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

GuruFocus.com

a year ago

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

MT Newswires

a year ago

JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating

Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gain

Simply Wall St.

a year ago

Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gain

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

GuruFocus.com

a year ago

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges

GuruFocus.com

a year ago

EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges

MT Newswires

a year ago

Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating

Share on Social Networks: